eNews July 29, 2020

The latest news affecting you and your customers… from the Independent Medical Specialty Dealers Association

How is COVID-19 affecting your business, your people, your customers? IMDA is a membership organization, and in times like these, we can all use some camaraderie. If you have a COVID story to share, advice to offer, or a warning to sound, send it to Mark Thill, IMDA’s communications director, at mdthill1913@gmail.com, with the subject line “IMDA COVID story.” We’ll compile them and send them back out to you.

Paradigms keep on shifting

Walmart will expand its Walmart Health concept to the state of Florida next year, beginning in Jacksonville, the company announced on July 22. Walmart Health facilities are said to offer transparent pricing for healthcare services, including primary and urgent care, labs, X-ray and diagnostics, counseling, dental, optical and hearing services – in one location. Walmart Health has existing facilities in Georgia and Arkansas, and plans on future locations in Illinois.

Cybersecurity: More important every day

Two medical device organizations announced a collaboration to advance medical device cybersecurity practices across the entire medical device lifecycle. The Association for the Advancement of Medical Instrumentation (AAMI) and the Archimedes Center for Medical Device Security will work together to connect their networks of medical device and health technology professionals to work on advancing security practices for life-saving devices. Potential outcomes include a standardized healthcare and medical device security curriculum for manufacturers and health delivery organizations.

Let your manufacturers know

Your manufacturer partners might be interested in listening to a prerecorded webinar on “Patient preference and Real World Evidence strategies to develop a patient-centered regulatory strategy,” presented earlier this month by the Medical Device Innovation Consortium. According to MDIC, patient preference information can help manufacturers, providers, and regulators understand the level and type of risks patients with a given condition would be willing to endure, and the level and type of benefit that would be most meaningful to them. Real-world evidence has the potential to give a more comprehensive view of how a technology performs, and enables manufacturers and regulators to understand the long-term outcomes of medical technology without delaying initial approval.